New imaging agent for metastatic clear cell kidney cancer
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a new radioactive imaging agent (111In-XYIMSR-01) to see how well it finds clear cell kidney cancer that has spread. It involves a special SPECT/CT scan and may help doctors better see where the cancer is.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- Your kidney cancer must be the clear cell type (confirmed by biopsy).
- You must have 2 to 10 visible cancer spots, each at least 1.5 cm on a recent CT or MRI scan (within the last 60 days).
- Your blood tests (liver, kidney, blood counts) need to be within certain ranges – your doctor can check these.
- You should not have had any cancer treatment (like immunotherapy or targeted therapy) in the past 12 months.
- You must not be pregnant or breastfeeding (if applicable).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called 177Lu-TLX250, which delivers radiation directly to kidney cancer cells. It is for people with advanced clear cell renal cell carcinoma that has returned or not responded to at least 2 prior treatments.
This early-phase study uses a special imaging agent called RYZ512 to see how it works in people with advanced clear cell kidney cancer that has spread. Participants will receive RYZ512 and have scans; you may qualify if you can pause certain medications temporarily.
This trial tests a new imaging agent (68Ga-NYM096) that may help doctors see whether a kidney mass is cancer before surgery. By undergoing a PET/CT scan with this agent, you might help doctors better plan your surgery and avoid unnecessary procedures.
This study tests a new imaging agent that may help doctors see kidney cancer and certain other tumors more clearly on PET/CT scans. It could help find cancer that has spread or come back after treatment.
This trial tests a new PET/CT scan that uses a special tracer to find clear cell kidney cancer. If you are scheduled for kidney tumor removal, this scan may help your surgeon see the cancer more clearly before surgery.
This study tests a special imaging agent (89Zr-TLX250) to help doctors see clear cell kidney cancer during PET/CT scans. It is for people in China who have a single small kidney mass and are already scheduled for surgery to remove it.
Hear when a new Renal Cell Carcinoma (Kidney Cancer) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.